Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Janux Therapeutics (JANX) PT Raised to $115 at Stifel
December 3, 2024 8:22 AM ESTStifel analyst Bradley Canino raised the price target on Janux Therapeutics (NASDAQ: JANX) to $115.00 (from $70.00) while maintaining a Buy rating.
The analyst comments "The JANX007 (PSMA-TRACTr) phase 1 update (LINK) leads us to increase our PoS for 2L and 3L mCRPC to 50% and 65%, respectively... More
Janux Therapeutics (JANX) PT Raised to $91 at Leerink Partners
December 3, 2024 6:55 AM ESTLeerink Partners analyst Jeffrey La Rosa raised the price target on Janux Therapeutics (NASDAQ: JANX) to $91.00 (from $79.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: Janux (JANX, OP) delivered with updated Ph 1 dose escalation data for lead candidate JANX007 (masked PSMA x... More
Stifel Reiterates Buy Rating on Janux Therapeutics (JANX)
December 3, 2024 5:27 AM ESTStifel analyst Bradley Canino reiterated a Buy rating and $70.00 price target on Janux Therapeutics (NASDAQ: JANX).
The analyst comments "Updated ph.1a JANX007 (PSMA-TRACTr) ~5L mCRPC data at therapeutic weekly dose regimens suggest a potentially guaranteed biochemical PSA response pre-Pluvicto, with three-quarters lasting >12wks.... More
Janux Therapeutics (JANX) PT Raised to $100 at BTIG, 'The World Is Not Enough — 007 Strikes Again Exceeding The Street's Highest Expectations'
December 3, 2024 5:26 AM ESTBTIG analyst Justin Zelin raised the price target on Janux Therapeutics (NASDAQ: JANX) to $100.00 (from $82.00) while maintaining a Buy rating.
The analyst comments "Janux surpassed the street's high expectations with their eagerly anticipated data update today (see our preview note here). Heading into the data, we've heard investor concerns that expectations were too high for JANX to meet our bull case scenario of >60% PSA50 at 12-wks,... More
